SCHEMBL24286080

SCHEMBL24286080

Cc1c(N)nc2ccc(-c3ccc4[nH]ccc4c3Cl)cn12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHFR P00374 2/20 0.36
▸ TP53 P04637 3/20 0.33
▸ GAA P10253 3/20 0.33
▸ MAPT P10636 3/20 0.33
▸ USP7 Q93009 1/20 0.33
▸ LRRK2 Q5S007 1/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.31
▸ THRB P10828 1/20 0.31
▸ JAK2 O60674 1/20 0.30
▸ RXFP1 Q9HBX9 1/20 0.30
▸ BRAF P15056 1/20 0.30
▸ DYRK3 O43781 1/20 0.30
▸ CCNT1 O60563 1/20 0.30
▸ CCNA2 P20248 1/20 0.30
▸ CDK2 P24941 1/20 0.30
▸ CDK9 P50750 1/20 0.30
▸ CDK5 Q00535 1/20 0.30
▸ DYRK1A Q13627 1/20 0.30
▸ CDK5R1 Q15078 1/20 0.30
▸ DYRK2 Q92630 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24285875 0.88 DHFR (0.37) DHFRTP53GAAMAPTUSP7
SCHEMBL29537495 0.76 ABL1 (0.39) LRRK2
SCHEMBL24286084 0.76 ABL1 (0.39) LRRK2
SCHEMBL24286655 0.76 MAPT (0.47) DHFRTP53GAAMAPTSMN1; SMN2
SCHEMBL24286665 0.75 AURKB (0.49) LRRK2JAK2CDK9CDK5DYRK1A
SCHEMBL24286014 0.74 USP7 (0.32) DHFRUSP7LRRK2
SCHEMBL7334380 0.71 PRKAB2 (0.38) GAAPIK3CD
SCHEMBL29538083 0.68 LRRK2 (0.42) LRRK2
SCHEMBL29537398 0.68 LRRK2 (0.42) LRRK2
SCHEMBL29537521 0.68 LRRK2 (0.42) LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds 1ST Biotherapeutics, Inc. (KR) 2023-09-05 — — US disclosed
US-20220087985-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS 1ST Biotherapeutics, Inc. (KR) 2022-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds NLRP3, NLRP1, KCNJ2 DHFR 3378/4885TP53 3431/4885GAA 3436/4885
US-20220087985-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS NLRP3, NLRP1, KCNJ2 DHFR 3378/4885TP53 3431/4885GAA 3436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback